Q4 2024 Earnings Call Transcript May 29, 2025 Roivant Sciences Ltd. misses on earnings expectations. Reported EPS is $-0.22 ...

Combined with the last dividend raise by +3.3% in December 2024, building upon the 10Y growth profile at +5.27%, we believe ...

Agilent Technologies A reported second-quarter fiscal 2025 earnings of $1.31 per share, which beat the Zacks Consensus ...

In a clinical pilot study, researchers from the Massachusetts Institute of Technology (MIT) and Massachusetts General ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Audit preparedness is essential for every clinical research site. By operationalizing compliance in your daily procedures, you can ...

Yet, I assess that Viking Therapeutics’s main growth vector will likely be imputed to its ability to commercialize and ...

exercise training studies utilising BFR as a clinical MSK rehabilitation tool were selected. The reference list of relevant papers was also examined. The exact search terms were: ‘blood flow ...

Guard Therapeutics today announced that an independent Data Safety Monitoring Committee (DSMC) has completed the second and final planned review of safety data from the ongoing Phase 2b clinical trial ...

Pfizer isn’t stopping to smell the roses on its speed run to secure a full FDA approval for its Braftovi combination therapy.

Report Ocean has published a new report on the Saudi Arabia Hematology and Flow Cytometry Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities.

The European Society for Medical Oncology (ESMO) is pleased to announce the publication of the latest version of the scale that measures the clinical benefit of cancer treatments, the ESMO-MCBS ...